Literature DB >> 25143569

Precision of vancomycin and daptomycin MICs for methicillin-resistant Staphylococcus aureus and effect of subculture and storage.

Carmen L Charlton1, Janet A Hindler2, John Turnidge3, Romney M Humphries4.   

Abstract

The reproducibility of vancomycin and daptomycin MICs, measured by broth microdilution (BMD) and Etest, was prospectively assessed for 10 methicillin-resistant Staphylococcus aureus (MRSA) isolates from the blood samples from patients on vancomycin therapy. The isolates were tested at the time of isolation from blood and following 5, 10, and 20 subcultures and at 1, 3, 6, and 12 months of storage at -70 °C. The MICs were determined by Etest and BMD using two different manufacturers (BBL and Difco) of cation-adjusted Mueller-Hinton broth (CA-MHB), and using three different drug powders: vancomycin from Sigma, vancomycin from Novation, and daptomycin from Cubist. The antimicrobial concentrations tested were 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, and 4.0 μg/ml. Two isolates were vancomycin intermediate and daptomycin nonsusceptible, and two isolates had reduced susceptibility to vancomycin (BMD MIC, 1.5 or 2.0 μg/ml). The vancomycin MICs were significantly higher in the BBL CA-MHB than those in the Difco CA-MHB, and with Sigma versus Novation vancomycin powder. The daptomycin MICs were also significantly higher in the BBL CA-MHB. The Etest MICs were significantly higher than those obtained by BMD for vancomycin but not for daptomycin. The average precision of the vancomycin BMD MICs when analyzing 20 results was ± 1.10-fold log2 dilutions, and it was ± 1.67-fold for daptomycin (10 results). The average precision for Etest was ± 1.11-fold for vancomycin and ± 1.16-fold for daptomycin. No significant change in MICs was noted following 5, 10, or 20 subcultures or at up to 6 months of frozen storage. However, the vancomycin MICs alone were significantly lower (0.74-fold) following 12 months of frozen storage. From these data, despite variations in CA-MHB and antimicrobial powder, the MIC result precision was <0.5 log2 dilutions in a single laboratory, suggesting that testing interdilution MICs (e.g., MICs between serial 2-fold dilutions) is a possibility. A more accurate method for measuring vancomycin MIC results is thus possible, but further standardization of BMD testing would be required to achieve this goal.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25143569      PMCID: PMC4313221          DOI: 10.1128/JCM.01571-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010.

Authors:  B Edwards; K Milne; T Lawes; I Cook; A Robb; I M Gould
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

2.  Product quality of parenteral vancomycin products in the United States.

Authors:  S Nambiar; R D Madurawe; S M Zuk; S R Khan; C D Ellison; P J Faustino; D J Mans; M L Trehy; M E Hadwiger; M T Boyne; K Biswas; E M Cox
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

Review 3.  The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.

Authors:  S J van Hal; T P Lodise; D L Paterson
Journal:  Clin Infect Dis       Date:  2012-02-02       Impact factor: 9.079

4.  Should laboratories test methicillin-resistant Staphylococcus aureus for elevated vancomycin minimum inhibitory concentrations by Etest as a driver of treatment changes?

Authors:  Romney M Humphries; Janet A Hindler
Journal:  Clin Infect Dis       Date:  2012-05-09       Impact factor: 9.079

Review 5.  Antimicrobial susceptibility testing: a review of general principles and contemporary practices.

Authors:  James H Jorgensen; Mary Jane Ferraro
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

6.  Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus.

Authors:  Franziska Ludwig; Becky Edwards; Timothy Lawes; Ian M Gould
Journal:  J Clin Microbiol       Date:  2012-08-01       Impact factor: 5.948

7.  Quality assessment of U.S. marketplace vancomycin for injection products using high-resolution liquid chromatography-mass spectrometry and potency assays.

Authors:  Michael E Hadwiger; Cynthia D Sommers; Daniel J Mans; Vikram Patel; Michael T Boyne
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

Review 8.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

9.  Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia.

Authors:  Natasha E Holmes; John D Turnidge; Wendy J Munckhof; J Owen Robinson; Tony M Korman; Matthew V N O'Sullivan; Tara L Anderson; Sally A Roberts; Sanchia J C Warren; Wei Gao; Benjamin P Howden; Paul D R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

Review 10.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

View more
  12 in total

1.  Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.

Authors:  Allison R McMullen; William Lainhart; Meghan A Wallace; Angela Shupe; Carey-Ann D Burnham
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-24       Impact factor: 3.267

Review 2.  CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests.

Authors:  Romney M Humphries; Jane Ambler; Stephanie L Mitchell; Mariana Castanheira; Tanis Dingle; Janet A Hindler; Laura Koeth; Katherine Sei
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

Review 3.  The Continued Value of Disk Diffusion for Assessing Antimicrobial Susceptibility in Clinical Laboratories: Report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group.

Authors:  Romney M Humphries; Susan Kircher; Andrea Ferrell; Kevin M Krause; Rianna Malherbe; Andre Hsiung; C A Burnham
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

4.  Analysis of MIC and Disk Diffusion Testing Variables for Gepotidacin and Comparator Agents against Select Bacterial Pathogens.

Authors:  L M Koeth; J M DiFranco-Fisher; N E Scangarella-Oman; L A Miller
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

5.  Identification of Low-Level Vancomycin Resistance in Staphylococcus aureus in the Era of Informatics.

Authors:  Bradley A Ford
Journal:  J Clin Microbiol       Date:  2016-02-10       Impact factor: 5.948

6.  Reproducible measurement of vancomycin MICs within the susceptible range in Staphylococcus aureus by a broth microdilution method with a "quasi-continuum" gradient of antibiotic concentrations.

Authors:  R Falcón; E M Mateo; A Talaya; E Giménez; V Vinuesa; M Á Clari; D Navarro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-07-25       Impact factor: 3.267

7.  Point-Counterpoint: Should Clinical Microbiology Laboratories Report Vancomycin MICs?

Authors:  Sara L Revolinski; Christopher D Doern
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

8.  Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus.

Authors:  Rocío Falcón; Eva Mateo; Rosa Oltra; Estela Giménez; Eliseo Albert; Ignacio Torres; David Navarro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-02-06       Impact factor: 3.267

9.  Antimicrobial Hydroxyapatite-Gelatin-Silica Composite Pastes with Tunable Setting Properties.

Authors:  Vuk Uskoković; Shreya Ghosh; Victoria M Wu
Journal:  J Mater Chem B       Date:  2017-07-13       Impact factor: 6.331

10.  Variability of Beta-Lactam Broth Microdilution for Pseudomonas aeruginosa.

Authors:  A A Bhalodi; N Oppermann; S A Campeau; R M Humphries
Journal:  Antimicrob Agents Chemother       Date:  2021-07-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.